Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Capital Expenditures (2022 - 2024)

Historic Capital Expenditures for Atara Biotherapeutics (ATRA) over the last 3 years, with Q4 2024 value amounting to $90000.0.

  • Atara Biotherapeutics' Capital Expenditures rose 10454.55% to $90000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $90000.0, marking a year-over-year decrease of 5500.0%. This contributed to the annual value of $246000.0 for FY2024, which is 7988.55% down from last year.
  • Latest data reveals that Atara Biotherapeutics reported Capital Expenditures of $90000.0 as of Q4 2024, which was up 10454.55% from $29000.0 recorded in Q2 2024.
  • Over the past 5 years, Atara Biotherapeutics' Capital Expenditures peaked at $2.6 million during Q1 2022, and registered a low of $29000.0 during Q2 2024.
  • In the last 3 years, Atara Biotherapeutics' Capital Expenditures had a median value of $132000.0 in 2022 and averaged $514727.3.
  • Per our database at Business Quant, Atara Biotherapeutics' Capital Expenditures soared by 11287.88% in 2023 and then plummeted by 9418.84% in 2024.
  • Over the past 3 years, Atara Biotherapeutics' Capital Expenditures (Quarter) stood at $37000.0 in 2022, then grew by 18.92% to $44000.0 in 2023, then surged by 104.55% to $90000.0 in 2024.
  • Its Capital Expenditures stands at $90000.0 for Q4 2024, versus $29000.0 for Q2 2024 and $127000.0 for Q1 2024.